We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+42.63%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$906M
AUM Growth
-$90.1M
Cap. Flow
-$241M
Cap. Flow %
-26.64%
Top 10 Hldgs %
57.8%
Holding
54
New
5
Increased
4
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
ALLK
Allakos
ALLK
+$17.3M
2
VRNA
Verona Pharma
VRNA
+$12.6M
3
TERN
Terns Pharmaceuticals
TERN
+$12M
4
PCVX icon
Vaxcyte
PCVX
+$10.3M
5
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$9.87M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$183M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$62.4M
3
HRMY icon
Harmony Biosciences
HRMY
+$33.8M
4
VTYX
Ventyx Biosciences
VTYX
+$12.5M
5
CLDX icon
Celldex Therapeutics
CLDX
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 97.5%
2 Materials 2.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
26
Zai Lab
ZLAB
$2.07B
$9.29M 1.03%
271,528
– –
ATXS
27
DELISTED
Astria Therapeutics
ATXS
$9.04M 1%
+1,000,000
New +$6.7M
MRUS
28
DELISTED
Merus
MRUS
$8.85M 0.98%
442,000
– –
ISEE
29
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$8.67M 0.96%
483,413
-4,755,221
-91% -$62.4M
IOBT
30
DELISTED
IO Biotech
IOBT
$8.17M 0.9%
3,015,545
– –
STSA
31
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$7.39M 0.82%
1,232,394
– –
DYN icon
32
Dyne Therapeutics
DYN
$5.01B
$7.34M 0.81%
577,642
– –
WHWK
33
Whitehawk Therapeutics
WHWK
$210M
$7.2M 0.79%
509,572
– –
GTH
34
DELISTED
Genetron Holdings Limited ADS
GTH
$6.35M 0.7%
2,708,058
– –
IOVA icon
35
Iovance Biotherapeutics
IOVA
$2B
$6.28M 0.69%
655,057
– –
BOLT icon
36
Bolt Biotherapeutics
BOLT
$7.59M
$5.73M 0.63%
193,565
– –
CLDX icon
37
Celldex Therapeutics
CLDX
$3.12B
$5.59M 0.62%
198,983
-359,653
-64% -$11M
DBVT
38
DBV Technologies
DBVT
$842M
$4.79M 0.53%
+270,888
New +$6.28M
OLMA icon
39
Olema Pharmaceuticals
OLMA
$1.03B
$4.66M 0.51%
1,689,515
– –
CMPX icon
40
Compass Therapeutics
CMPX
$351M
$4.56M 0.5%
2,000,000
– –
ARWR icon
41
Arrowhead Research
ARWR
$12.4B
$4.54M 0.5%
137,411
– –
ALGS icon
42
Aligos Therapeutics
ALGS
$30.1M
$3.9M 0.43%
141,881
– –
GRCL
43
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$3.1M 0.34%
961,359
– –
SERA icon
44
Sera Prognostics
SERA
$76.8M
$2.97M 0.33%
1,856,011
– –
CDXS icon
45
Codexis
CDXS
$157M
$2.35M 0.26%
388,144
– –
UTRS
46
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$1.76M 0.19%
110,783
– –
ASLN
47
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$1.7M 0.19%
71,023
– –
RZLT icon
48
Rezolute
RZLT
$478M
$1.34M 0.15%
489,473
– –
QTTB icon
49
Q32 Bio
QTTB
$494M
$596K 0.07%
20,559
– –
DTIL icon
50
Precision BioSciences
DTIL
$196M
$182K 0.02%
4,675
– –
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
LWIC
Leith Wheeler Investment Counsel Vancouver, British Columbia, Canada $1.21B AUM 12.04% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return

Vivo Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Vivo Capital held 54 positions worth $906M, down 9% from $996M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Vivo Capital withdrew a net $241M in Q3 2022, closing 3 positions and reducing 7 holdings. Its most notable exit was Sierra Oncology, Inc. Common Stock, an estimated $183M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Materials.

Against the trend, Vivo Capital opened a new position in Allakos worth $25.2M.

  • Vivo Capital's largest Q3 2022 buy was Allakos: 4,120,134 shares worth $25.2M.
  • Vivo Capital added most to Verona Pharma in Q3 2022, an estimated $12.6M increase.
  • Vivo Capital's biggest Q3 2022 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $62.4M.
  • Vivo Capital fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $183M.
  • Vivo Capital's ten largest holdings make up 58% of its $906M portfolio in Q3 2022.
  • Vivo Capital opened 5 new positions and closed 3 in Q3 2022.
  • Vivo Capital's portfolio value fell 9% quarter-over-quarter to $906M.

Based on Vivo Capital's 13F filing for Q3 2022, filed 14 Nov 2022.